Is Amneal Pharmaceuticals (AMRX) Fairly Valued After Its Sharp Rerating?

Amneal Pharmaceuticals (AMRX) is back in focus after a recent review highlighted strong long term shareholder returns, alongside slower projected revenue growth, stagnant free cash flow margins, and mixed outcomes from past growth initiatives.

See our latest analysis for Amneal Pharmaceuticals.

At a share price of $18.04, Amneal Pharmaceuticals has seen strong short term momentum, with a 30 day share price return of 11.02% and year to date share price return of 42.50%, on top of a 1 year total shareholder return of 118.93% and a 3 year total shareholder return above 4x.

If strong returns at Amneal have you looking for what else is working in healthcare, it may be worth scanning other opportunities in 39 healthcare AI stocks

After a sharp rerating and only a small discount to analyst targets, Amneal Pharmaceuticals still screens at a sizeable gap to some fair value estimates. Is the market rightly cautious, or is it underpricing what is already in plain sight?

Most Popular Narrative: 1.2% Undervalued

With Amneal Pharmaceuticals last closing at $18.04 against a most-followed fair value of $18.25, the current price sits very close to that narrative anchor while still leaving a small perceived upside tied to execution.

Strategic partnerships (such as with Metsera for GLP-1s and ApiJect for U.S. injectables), expansion into high-growth categories (GLP-1s, complex injectables, and biosimilars), and the upcoming launches in international markets (particularly India and Europe) provide new avenues for incremental revenue and profit growth in the coming years.

Read the complete narrative.

Want the full playbook behind that fair value for Amneal Pharmaceuticals? The core story leans on faster earnings, richer margins, and a future valuation multiple that has to work hard to justify itself.

Result: Fair Value of $18.25 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, the Amneal Pharmaceuticals story can be knocked off course if U.S. generics pricing pressure persists or if key biosimilar and specialty launches are delayed.

Find out about the key risks to this Amneal Pharmaceuticals narrative.

Another View on Amneal Pharmaceuticals Valuation

While the analyst fair value narrative pegs Amneal Pharmaceuticals close to $18.25, the SWS DCF model paints a very different picture, with an estimated future cash flow value of $53.36 at a share price of $18.04. That gap frames Amneal as heavily undervalued on this method, or as a test of how much faith you place in long range cash flow assumptions.

If you want to see how that long range cash flow view was built, take a closer look at how the SWS DCF model works in practice, then decide which set of assumptions feels more realistic for you as an investor. Look into how the SWS DCF model arrives at its fair value.

Next Steps

If the split view on Amneal Pharmaceuticals has you torn, now is a good time to look through the numbers yourself and decide what matters most for you. You can start with 3 key rewards and 3 important warning signs.

Looking for more investment ideas beyond Amneal Pharmaceuticals?

If Amneal Pharmaceuticals has sharpened your focus, do not stop here. Broaden your watchlist with other stock ideas that fit different goals and risk levels.

• Target potential mispricings by scanning companies that currently look out of favor yet financially robust with the 49 high quality undervalued stocks.
• Strengthen your income stream by hunting for stocks built around reliable cash returns using the 8 dividend fortresses.
• Prioritize resilience and sleep a little easier at night by zeroing in on companies that appear built to weather shocks through the 82 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com